Drug Profile
Research programme: glycan and glycolipid synthesis inhibitors - BioMarin Pharmaceutical
Latest Information Update: 09 Apr 2018
Price :
$50
*
At a glance
- Originator Zacharon Pharmaceuticals
- Developer BioMarin Pharmaceutical
- Class Small molecules
- Mechanism of Action Ganglioside inhibitors; Glycosaminoglycan inhibitors; Polysaccharide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer; Gangliosidoses; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis III
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gangliosidoses in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-I in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in USA